Benethera

Benethera is a South Korean biotechnology company specializing in the discovery and development of innovative antibody-based therapeutics for autoimmune and inflammatory disorders. Founded in 2020 and based in Incheon's Songdo Bio Cluster, the company leverages its proprietary protein engineering expertise to create high-affinity monoclonal and bispecific antibodies. Their lead pipeline candidate, BNT-001, is a bispecific antibody targeting both IL-17A and IL-17F that has entered Phase 1 clinical testing for the treatment of psoriasis. Other programs include BNT-002, targeting IL-4Rα for atopic dermatitis, and BNT-003, targeting TSLP for asthma. Benethera aims to provide differentiated treatment options with enhanced efficacy and safety compared to existing biologics. The leadership team comprises industry veterans with extensive experience in global drug development and commercialization.